Literature DB >> 17937086

Safety and effectiveness of tinzaparin sodium in the management of recurrent pregnancy loss.

S Dendrinos1, I Kalogirou, E Makrakis, T Theodoridis, E A Mahmound, V Christopoulou-Cokkinou, G Creatsas.   

Abstract

PURPOSE: To assess the safety and efficacy of tinzaparin sodium for the management of recurrent pregnancy loss.
METHODS: The study included 62 women with a history of recurrent pregnancy loss and at least one factor of thrombophilic disorder. Of these, 31 received 50 IU/kg of tinzaparin sodium daily (Group A), and 33 received 100 mg of aspirin daily (Group B).
RESULTS: Group A subjects (receiving tinzaparin sodium) had six new abortions, whereas Group B subjects (receiving aspirin) had 11 (significant difference). Cases of intrauterine growth restriction (none in Group A and 2 in Group B), placental abruption (one in Group A and 4 in Group B), and preeclampsia (one in Group A and 3 in Group B) were comparable between the two groups. Finally coagulation disorders (none in Group A and 6 in Group B) were significantly fewer in Group A.
CONCLUSION: A 50 IU/kg daily dose of tinzaparin sodium seems to be effective for the management of recurrent abortion and has high standards of safety.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17937086

Source DB:  PubMed          Journal:  Clin Exp Obstet Gynecol        ISSN: 0390-6663            Impact factor:   0.146


  9 in total

1.  Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.

Authors:  Eva N Hamulyák; Luuk Jj Scheres; Mauritia C Marijnen; Mariëtte Goddijn; Saskia Middeldorp
Journal:  Cochrane Database Syst Rev       Date:  2020-05-02

Review 2.  Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant.

Authors:  M Empson; M Lassere; J Craig; J Scott
Journal:  Cochrane Database Syst Rev       Date:  2005-04-18

Review 3.  Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period.

Authors:  Rebecca Tooher; Simon Gates; Therese Dowswell; Lucy-Jane Davis
Journal:  Cochrane Database Syst Rev       Date:  2010-05-12

4.  Reducing stillbirths: prevention and management of medical disorders and infections during pregnancy.

Authors:  Esme V Menezes; Mohammad Yawar Yakoob; Tanya Soomro; Rachel A Haws; Gary L Darmstadt; Zulfiqar A Bhutta
Journal:  BMC Pregnancy Childbirth       Date:  2009-05-07       Impact factor: 3.007

5.  Care prior to and during subsequent pregnancies following stillbirth for improving outcomes.

Authors:  Aleena M Wojcieszek; Emily Shepherd; Philippa Middleton; Zohra S Lassi; Trish Wilson; Margaret M Murphy; Alexander Ep Heazell; David A Ellwood; Robert M Silver; Vicki Flenady
Journal:  Cochrane Database Syst Rev       Date:  2018-12-17

6.  Venous thromboembolism prophylaxis for women at risk during pregnancy and the early postnatal period.

Authors:  Philippa Middleton; Emily Shepherd; Judith C Gomersall
Journal:  Cochrane Database Syst Rev       Date:  2021-03-29

7.  Low molecular weight heparin use in unexplained recurrent miscarriage.

Authors:  Halide Yuksel; Semra Kayatas; Aysen Telce Boza; Murat Api; A Aktug Ertekin; Cetin Cam
Journal:  Pak J Med Sci       Date:  2014 Nov-Dec       Impact factor: 1.088

8.  Medications for preventing hypertensive disorders in high-risk pregnant women: a systematic review and network meta-analysis.

Authors:  Tippawan Liabsuetrakul; Yoshiko Yamamoto; Chanon Kongkamol; Erika Ota; Rintaro Mori; Hisashi Noma
Journal:  Syst Rev       Date:  2022-07-01

Review 9.  Antithrombotic Treatment for Recurrent Miscarriage: Bayesian Network Meta-Analysis and Systematic Review.

Authors:  Tianyi Zhang; Xiaofei Ye; Tiantian Zhu; Xiang Xiao; Yuzhou Liu; Xin Wei; Yu Liu; Cheng Wu; Rui Guan; Xiao Li; Xiaojing Guo; Huili Hu; Jia He
Journal:  Medicine (Baltimore)       Date:  2015-11       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.